Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Ratio (2016 - 2025)

Cytosorbents' Equity Ratio history spans 15 years, with the latest figure at 0.13 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.13 for Q4 2025, down 43.02% from a year ago — trailing twelve months through Dec 2025 was 0.13 (down 43.02% YoY), and the annual figure for FY2025 was 0.13, down 43.02%.
  • Equity Ratio for Q4 2025 was 0.13 at Cytosorbents, down from 0.2 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2021 to a low of 0.13 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.45 (2023), against an average of 0.48.
  • The sharpest move saw Equity Ratio surged 83.26% in 2021, then plummeted 47.12% in 2024.
  • Year by year, Equity Ratio stood at 0.7 in 2021, then decreased by 19.97% to 0.56 in 2022, then decreased by 20.75% to 0.44 in 2023, then plummeted by 47.12% to 0.23 in 2024, then tumbled by 43.02% to 0.13 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.13, 0.2, and 0.24 for Q4 2025, Q3 2025, and Q2 2025 respectively.